Market Position
Market Position of MITTA (Minimally-Invasive Targeted Tumor Ablation) in Cancer Treatment
Minimally Invasive
PTS is intratumorally injected into tumor cells via percutaneous puncture by utilizing bronchoscopy, endoscope, or image-guided equipment (ultrasound or CT) to locate the tumor. Comparing to the traditional open surgery (i.e. laparotomy), the minimal-invasive surgery provides small lesion, less pain, less bleeding, and less infection after surgery. Also, there is no adhesion and no stitch removal required after surgery; as a result, the recovery time is short without leaving an ugly surgical scar, which is of great significance to the patient's postoperative recovery.
Targeted
PTS is specifically administered into tumor cells through intratumoral injection without affecting adjacent normal tissues. Moreover, In vitro studies show that PTS can penetrate the cancer cell membrane quickly once contacting with cancer cells and accumulate in the cytoplasm in a large amount, and the PTS concentration is dozens of times higher in cancer cells than in normal cells, which eventually leads to tumor necrosis. With administration specifically to the tumor site and killing selectivity PTS possessed to the tumor cells, these two characteristics constitute PTS’ targeted feature.
Quick Tumor Ablation
PTS is a small molecule and chemical anticancer drug that caused tumor cell necrosis 24 hours after minimally invasive intervention but only caused minimal damage to the adjacent normal cells.
Minimally Invasive Targeted Tumor Ablation (MITTA)
Owing to the above features, we named the PTS treatment “Minimally Invasive Targeted Tumor Ablation (MITTA)." Furthermore, based on a series of clinical trials in solid tumors, including head and neck cancer, breast cancer, lung cancer, and liver cancer, not only has PTS demonstrated its efficacy in ablating malignant tumors, but also its safety through administration specifically to the tumor site utilizing image-guided equipment and the selectivity PTS possessed to the tumor cells that caused no side effects like traditional chemotherapy does.
Market Position of Targeted Chemical Ablation Agents in Cancer Treatment
Complied by Gongwin Biopharm Co., Ltd. (2024)